Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer

Prostate

Volumn 76, Issue 3, 2016, Pages 325-334

  DiPippo, Vincent A ^a   Nguyen, Holly M ^b   Brown, Lisha G ^b   Olson, William C ^a   Vessella, Robert L ^b   Corey, Eva ^b  

^a Clinical Research   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ADC; patient derived xenografts; prostate cancer; PSMA

Indexed keywords

ANDROGEN RECEPTOR; ANTIBODY CONJUGATE; ENZALUTAMIDE; GLUCOCORTICOID RECEPTOR; PLACEBO; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY CONJUGATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PHENYLTHIOHYDANTOIN; PSMA ADC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG SCREENING; MORTALITY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TRENDS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84954363587     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23124     Document Type: Article

References (38)

1. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP,. Treating patients with metastatic castration-resistant prostate cancer: A comprehensive review of available therapies. J Urol 2015; DOI: 10.1016/j.juro.2015.06.106. In press.
2. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F,. Castration-resistant prostate cancer: From new pathophysiology to new treatment. Eur Urol 2014; 65: 289-299.
3. Bishr M, Saad F,. Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013; 10: 522-528.
4. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS,. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
6. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim C-S, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin M-E, Venner PM, Tombal B,. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-433.
7. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin M-E, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE,. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-160.
8. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J,. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028-1038.
9. Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F,. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol 2015; 26: 2044-2056.
10. Wong YNS, Ferraldeschi R, Attard G, de Bono JS,. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol 2014; 11: 365-376.
11. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen C, Higano CS, Beer TM, Hung DT, Scher HI, Jung M, Sawyers CL,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
12. Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA,. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 2012; 287: 3777-3787.
13. Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah J-A, Templeton AJ, Knox JJ, Tannock IF, Sridhar SS, Joshua AM,. Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. Prostate 2014; 74: 1462-1464.
14. Bambury RM, Louw J, Krupa R, Danila D, Arslan Z, Schreiber NA, Jendrisak A, Marrinucci D, Dittamore R, Scher HI,. Characteristics of de novo resistance to androgen targeting therapeutics (AR Tx) through circulating tumor cells (CTCs) analysis in metastatic castration resistant prostate cancer (mCRPC) patients. Ann Oncol 2014; 25 (suppl 4): iv79.
15. Schrader AJ, Boegemann M, Ohlmann C-H, Schnoeller TJ, Krabbe L-M, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV,. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65: 30-36.
16. Evans CP, Lara PN Jr,. Prostate cancer: Predicting response to androgen receptor signalling inhibition. Nat Rev Urol 2014; 11: 433-435.
17. Boyd LK, Mao X, Lu Y-J,. The complexity of prostate cancer: Genomic alterations and heterogeneity. Nat Rev Urol 2012; 9: 652-664.
18. Ghosh A, Heston WDW,. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-539.
19. Kularatne SA, Wang K, Santhapuram H-KR, Low PS,. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharmacol 2009; 6: 780-789.
20. Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA,. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38: 696-701.
21. 18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 2015; 17: 565-574.
22. Petrylak DP, Kantoff PW, Mega AE, Vogelzang NJ, Stephenson J, Fleming MT, Stambler N, Petrini M, Huang K, Israel RJ,. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. J Clin Oncol 2013; 31 suppl;abstr 119.
23. Petrylak DP, Vogelzang NJ, Chatta GS, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer BG, Wadlow RC, Shore ND, Stambler N, DiPippo VA, Israel RJ,. A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz). J Clin Oncol 2015; 33 suppl;abstr 144.
24. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC,. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006; 12: 2591-2596.
25. Wang X, Ma D, Olson WC, Heston WD,. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 2011; 10: 1728-1739.
26. DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E,. Efficacy studies of an antibody-drug conjugate PSMA ADC in patient-derived prostate cancer xenografts. Prostate 2015; 75: 303-313.
27. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL,. Glucocorticoid receptor confers resistance to anti-androgens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-1322.
28. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, de Bono JS, Massard C,. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013; 24: 1807-1812.
29. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN,. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24: 1802-1807.
30. Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong Y-N, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS,. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737-746.
31. James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Spears MR, Millman R, Parker C, Ritchie AWS, Russell JM, Staffurth J, Jones RJ, Tolan SP, Wagstaff J, Protheroe A, Srinivasan R, Birtle AJ, O'Sullivan JM, Cathomas R, Parmar MMK,. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT 00268476). J Clin Oncol 2015; 33 suppl;abstr 5001.
32. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M,. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149-158.
33. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr., Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV,. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-6362.
34. Wright GL Jr., Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R,. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-334.
35. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL,. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA 2011; 108: 9578-9582.
36. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu C-L, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA,. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2012; 2: 995-1003.
37. Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC,. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 2015; 75: 242-254.
38. Petrylak DP, Smith DC, Appleman LJ, Fleming MT, Hussain A, Dreicer R, Sartor AO, Shore ND, Vogelzang NJ, Youssoufian H, DiPippo VA, Stambler N, Huang K, Israel RJ,. A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32 suppl;abstr 5023.